Neurovascular Devices for Hemorrhagic Stroke Market Snapshot 2024-2028
Overview
Valued at ~$1.9 billion in 2023, the neurovascular devices for hemorrhagic stroke market is
projected to reach ~$2.6 billion by 2028, increasing at a CAGR of 6.1% over
the 2023-2028 forecast period. This Market Snapshot is part of LSI’s Market Intelligence platform, your
one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and
deal-tracking, curated insights, and more.
The neurovascular devices for hemorrhagic stroke market encompasses products employed in the treatment of:
Intracerebral hemorrhage
Subarachnoid hemorrhage
Products included within the scope of this analysis include:
Microcatheters and related accessories (guidewires, guiding catheters, sheaths) for neurovascular access
Embolization devices (e.g., coils)
Surgical clips
Flow-diverting stents
This Market Snapshot is intended to provide a high-level overview of the global market for neurovascular devices
for hemorrhagic stroke, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
Neurovascular Devices for Hemorrhagic Stroke Market Snapshot Summary
| Snapshot Aspect | Data and Details |
| Base Year for Estimate | 2023 |
| Forecast Period | 2023 - 2028 |
| Market Size in 2023 | $1.9 billion |
| CAGR | 6.1% |
| Projected Market Size in 2028 | $2.6 billion |
Neurovascular Devices for Hemorrhagic Stroke Market Insights
The neurovascular devices for hemorrhagic stroke market is primarily driven by the global incidence of stroke,
which remains a significant public health concern. Each year, over 12.2 million people experience a stroke, with
hemorrhagic stroke accounting for 37.7% of these cases. This type of stroke, characterized by bleeding in or
around the brain, is far deadlier than ischemic
stroke due to its sudden onset and high mortality
rates—especially in regions with limited healthcare access.
What sets hemorrhagic stroke apart is that, unlike ischemic stroke, it cannot be treated with clot-busting
drugs, which are the standard of care for ischemic strokes. As a result, the neurovascular devices for
hemorrhagic stroke market leans more heavily toward device-based interventions.
In less
developed countries, particularly those in Asia, market growth is being driven by increased utilization
of stroke treatment and prevention as well as increasing incidence due to stable risk factors and aging
populations. Moreover, advancements in minimally invasive technologies, such as smaller, more precise tools for
navigating tortuous brain regions, will be critical to addressing unmet needs in this space. While dominant
players like Stryker continue to innovate, there remains a space for emerging companies to improve access to
care, particularly in hard-to-treat cases.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the neurovascular devices
for hemorrhagic stroke market. This includes estimated market revenue and market share for key players, such as
MicroVention/Terumo, Stryker, and Cordis.
Select Market Events
| Company | Date | Type | Event |
|
Johnson & Johnson
|
3/2024 | Product Launch | CERENOVUS announced the launch of its TRUFILL n-BCA Liquid Embolic System Procedural Set for hemorrhagic stroke. |
|
Stryker
|
9/2024 | Acquisition | Stryker completes the acquisition of NICO Corporation. |
Key Companies Covered
Abbott
Boston Scientific
Cerenovus
Evasc
Johnson & Johnson
MicroPort Scientific
Microvention
Micrus
Penumbra
Shape Memory Medical
Stryker
Terumo
